Leading Growth Driver in the Budesonide Market in 2025: Impact Of Respiratory Diseases Growth On The Market Driver's Influence

Which drivers are expected to have the greatest impact on the over the budesonide market's growth?
The increasing prevalence of respiratory diseases is also expected to drive the growth of the budesonide market. Respiratory diseases refer to medical conditions that impact the organs and tissues involved in gas exchange in air-breathing animals. This rise in respiratory diseases is primarily due to growing air pollution, particularly exposure to particulate matter and allergens, which significantly affect asthma and chronic obstructive pulmonary disease (COPD). Budesonide is used to treat asthma and COPD, reducing inflammation, enhancing airflow, and alleviating symptoms such as wheezing and shortness of breath. In May 2024, the National Center for Health Statistics (NCHS) reported that the prevalence of current asthma among U.S. adults aged 18 and older increased from 8.4% in 2021 to 8.7% in 2022. Moreover, the number of asthma episodes in the past 12 months increased from 3.3% in 2021 to 3.7% in 2022. Thus, the rising prevalence of respiratory diseases is propelling the growth of the budesonide market.

Get Your Budesonide Market Report Here:
https://www.thebusinessresearchcompany.com/report/budesonide-global-market-report

What is the future CAGR of the budesonide market, and how will it impact industry expansion?
The budesonide market has shown strong growth, expected to rise from $9.72 billion in 2024 to $10.36 billion in 2025 at a CAGR of 6.6%. Growth in previous years was driven by the increasing prevalence of respiratory diseases, greater awareness of inhaled corticosteroids, the introduction of combination therapies, expansion of healthcare access, and the use of budesonide for off-label inflammatory bowel disease treatment.

The budesonide market is projected to experience solid growth, expanding to $13.25 billion by 2029 at a CAGR of 6.3%. Key factors driving this expansion include increasing demand for effective treatments, novel drug delivery systems, rising use of budesonide, an aging population prone to asthma, and the growing availability of generic budesonide products. Notable trends include the rising adoption of biologics and biosimilars, advancements in drug delivery technology, regulatory approvals for new formulations, continued innovations in drug administration, and broader technological developments in the pharmaceutical sector.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21121&type=smp

What are the most significant trends transforming the budesonide market today?
In the budesonide market, companies are advancing oral therapy formulations to enhance patient convenience and adherence for respiratory conditions. For instance, in February 2024, Takeda Pharmaceuticals, a Japan-based company, received FDA approval for EOHILIA, an oral budesonide suspension. This is the first FDA-approved oral medication for eosinophilic esophagitis (EoE) in patients aged 11 and older, providing a convenient treatment option for managing this condition.

Which key market segments comprise the budesonide market and drive its revenue growth?
The budesonide market covered in this report is segmented -

1) By Type: Inhalation Powder, Aerosols, Injectable Suspension, Tablets And Capsules
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Nose Disease Treatment, Inflammatory Bowel Disease Treatment, Respiratory Disease Treatment, Other Applications

Subsegments:
1) By Inhalation Powder: Dry Powder Inhalers (DPI), Soft Mist Inhalers (SMI)
2) By Aerosols: Metered-Dose Inhalers (MDI), Breath-Activated Inhalers
3) By Injectable Suspension: Pre-filled Syringes, Vials
4) By Tablets And Capsules: Oral Tablets, Oral Capsules

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21121

What regions are at the forefront of budesonide market expansion?
North America was the largest region in the budesonide market in 2024. The regions covered in the budesonide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the leading players fueling growth in the budesonide market?
Major companies operating in the budesonide market are AstraZeneca AB, Novartis AG, Takeda Pharmaceuticals Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz AG, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Lupin Limited, Orion Corporation, Salix Pharmaceuticals Inc., Synmosa Biopharma Corporation, Cosmo Pharmaceuticals N.V., Skyepharma Holdings Inc., Manus Aktteva Biopharma LLP, Cennet Biopharma Private Limited, Santarus Inc., SiNi Pharma Private Limited, Shanghai Sine Promod Pharmaceutical Co. Ltd.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21121&type=smp

What Is Covered In The Budesonide Global Market Report?

•Market Size Forecast: Examine the budesonide market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the budesonide market for a structured understanding.
•Key Players Overview: Analyze major players in the budesonide market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the budesonide market.
•Segment Contributions: Evaluate how different segments drive overall growth in the budesonide market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the budesonide market.
•Industry Challenges: Identify potential risks and obstacles affecting the budesonide market.
•Competitive Landscape: Review strategic developments in the budesonide market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.